DeepMind Spin-off Aims To Halve Drug Discovery Times Following Big Pharma Deals

The head of Google DeepMind believes its drug discovery spinout will halve the time taken to find new medicines, attracting the attention of the world's biggest pharmaceutical companies which are looking to artificial intelligence to revolutionise the lengthy process. From a report: Speaking to the Financial Times, Demis Hassabis, who co-founded Google's AI unit and also leads the drugs offshoot Isomorphic Labs, said the goal was to reduce the discovery stage -- when potential drugs are identified before clinical trials -- from the average of five years to two. "I think that would be success for us and be very meaningful," he said. Hassabis stated the goal days after announcing Isomorphic Lab's first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform the finances of the unprofitable group. Isomorphic Labs uses an AI platform to predict biochemical structures, which aids the creation of new drugs by recommending which potential compounds will have the desired impact in the body. Including clinical trials, it often takes up to a decade to discover and develop a new drug, costing on average about $2.7bn, according to research by the Tufts Center for the Study of Drug Development. Large drugmakers, under pressure to fill their pipelines with new potential medicines while existing ones face patent cliffs, when they will face far cheaper generic competition, are eager for new ways to shorten the process. As healthcare systems around the world put pressure on drug prices, pharma companies are also looking for ways to cut costs in research and development. Hassabis said that many drugmakers had also been eager to partner with Isomorphic but the company wanted to focus on collaborations that could improve its technology.

Read more of this story at Slashdot.